Research programme: YKL 40 inhibitor therapeutics
Latest Information Update: 28 Jun 2022
Price :
$50 *
At a glance
- Originator OncoArendi Therapeutics
- Developer Molecure
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Chitinase 3 like protein 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Idiopathic pulmonary fibrosis
Most Recent Events
- 07 Feb 2022 Preclinical trials in Cancer in Poland (Parenteral) (OncoArendi Therapeutics pipeline,
- 24 Jan 2022 Preclinical trials in Idiopathic pulmonary fibrosis in Poland (Parenteral) (OncoArendi Therapeutics pipeline,